Vizimpro
Term · Oncology and biomedicine · MLC-T-ONC-009299
A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Vizimpro blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called dacomitinib and PF-00299804.
| Identifier | MLC-T-ONC-009299 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | dacomitinib; PF-00299804 |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009299",
"term": "Vizimpro",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Vizimpro blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called dacomitinib and PF-00299804.",
"synonyms": [
"dacomitinib",
"PF-00299804"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/vizimpro/"
}
Record 17,310 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.